← Leaderboards
David A. Gewirtz
Virginia Commonwealth University
$3,700,163
Attributed
$8,385,095
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,385,095 · 6
By mechanism
R01$8,034,481 · 5
R21$350,614 · 1
Top collaborators
- Hisashi Harada14 shared
- Joseph William Landry14 shared
- Mohamad Imad Damaj9 shared
- Antonio Abbate2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Hisashi Harada$3,277,011
- Joseph William Landry$2,951,878
- Mohamad Imad Damaj$10,091,132
- Aron H Lichtman$10,846,349
- Mary E Abood$7,791,067
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsEffectivenessDoseTumorPreventNeoplastic CellGrowthPropertyCellsImmuneChemotherapyAnimalsToxic EffectMediatingMortalityMouse ModelBaseCell GrowthDesignExposure ToClinical TrialsAftercareResponseMalignant Neoplasm Of Lung
Grant awards (27)
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$517,388
R01 · FY2025 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$491,519
R01 · FY2024 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$45,933
R01 · FY2024 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2023 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$273,905
R01 · FY2023 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$66,687
R01 · FY2023 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$43,892
R01 · FY2023 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2022 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$386,245
R01 · FY2022 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$56,404
R01 · FY2022 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$509,377
R01 · FY2021 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2021 · CA · contact PI
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$259,419
R01 · FY2021 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2020 · CA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,604
R01 · FY2020 · CA · contact PI
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$324,275
R01 · FY2020 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2019 · CA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$332,443
R01 · FY2019 · CA · contact PI
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$314,547
R01 · FY2019 · CA
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,846
R01 · FY2018 · CA · contact PI
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy$281,441
R01 · FY2018 · CA
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$342,964
R01 · FY2017 · CA · contact PI
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy$363,112
R01 · FY2016 · CA · contact PI
Protection from Radiation Induced Cardiomyopathy$156,260
R21 · FY2014 · CA · contact PI
Protection from Radiation Induced Cardiomyopathy$194,354
R21 · FY2013 · CA · contact PI
Development of Vascular Disrupting Agents$273,356
R01 · FY2010 · CA · contact PI
Development of Vascular Disrupting Agents$270,775
R01 · FY2009 · CA · contact PI